The Technology Impact Award provides seed funding to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists.

The award focuses on areas where technological innovation stands to benefit the field and cancer patients most, and that will ultimately lead to effective next generation cancer immunotherapies. These technologies may include but are not limited to:

- New bioinformatics methods or technologies that speed collection and analysis of large sets of patient-derived biological data

- Computer simulations for modeling biological systems and responses to immunotherapy

- Tools and methods that improve profiling of tumors to inform therapeutic strategies

- Real-time visualizations of molecular and cellular activity to improve tracking of responses to immunotherapy

- In vitro tissue culture systems that recapitulate the interactions between primary tumor cells and the immune system

Duration

12-24 months

Applicants must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation.

The grant will be awarded to a scientist who describes an extraordinarily novel, yet practical research plan that is creative and technically sophisticated.

Joint submissions from collaborators will also be considered. (The collaborators will share the award.) Each collaborator must meet the eligibility criteria.

Selected projects that meet their 12 and 24 month milestones may be eligible for follow-on funding that will enable the established proof-of-concept technology to be developed into a methodology that improves cancer immunotherapy research worldwide

Letters of intent must be submitted electronically at https://www.grantrequest.com/SID_205?SA=SNA&FID=35050
Supporting documentation:

- Abstract of research in nontechnical English explaining the significance of the new technology platform and its impact on the field of cancer immunotherapy. Not to exceed 250 words.

- An initial research concept (succinct description of the proposed research plan with specific aims and timelines, description of the how the proposed technology platform has the potential to transform the field of cancer immunotherapy), not to exceed 3 pages.

- Brief description of your current research.

- Curriculum vitae and bibliography (limit bibliography to past 5 years or publications relevant to proposed research).

- If applicable, curriculum vitae for all group members, as well as a description of each member's research focus.